Key Highlights: Implications: HRV Pharma’s ₹150 crore investment strengthens its position in complex and high-value pharmaceutical segments, particularly synthetic peptides and high-potency oncology A...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...
Key Highlights: Implications: By consolidating three injectable-focused entities under one legal umbrella, Aurobindo can streamline manufacturing, R&D, and commercial operati...
Key Highlights: Implications: If completed, the transaction would likely be a strong validation event for mid-sized Indian pharmaceutical businesses that combine branded generics, nu...
Latest Developments in USFDA Inspections India plays a crucial role in the global pharmaceutical supply chain, supplying a large share of generic medicines to markets around the world. As Indian...
Key Highlights: Implications: This is a strategic diversification move: Anupam Rasayan is using Bliss GVS to enter pharmaceutical formulations and move further up the healthcare value chai...
Latest Developments in Global Pharma Supply Chains The COVID-19 pandemic exposed critical vulnerabilities in global pharmaceutical supply chains, highlighting the risks associated with overrelia...
Key Highlights: Implications: The partnership lets Zydus scale its semaglutide franchise while tapping Torrent’s strong chronic-care reach, accelerating GLP‑1 penetration without stretchin...
